Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ginsenoside C-K in preparation of antiepileptic drug

An anti-epileptic drug and technology of ginsenosides, applied in the field of medicine, can solve problems such as the anti-epileptic effect of ginsenosides C-K not involved

Inactive Publication Date: 2016-12-21
欧阳冬生 +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the above patent content, the components of ginsenoside saponins are a mixture and the total content of ginsenoside saponins is less than 98%, and the content of five monomeric compounds is less than 50%, none of which involves the antiepileptic effect of ginsenoside C-K

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside C-K in preparation of antiepileptic drug
  • Application of ginsenoside C-K in preparation of antiepileptic drug
  • Application of ginsenoside C-K in preparation of antiepileptic drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1 Ginsenoside C-K intervenes in the acute epilepsy model induced by lithium chloride-pilocarpine

[0014] 1. Experimental method

[0015] 1.1 Dose Design and Grouping

[0016] The experiment was divided into normal control group, epilepsy model group, sodium valproate positive control group (400mg / kg), low-dose ginsenoside C-K group (80mg / kg), middle-dose ginsenoside C-K group (160mg / kg). (See Table 1).

[0017] Table 1 Experimental grouping and dose design

[0018]

[0019] 1.2 Experimental steps

[0020] 60 SPF grade healthy male SD rats (body weight 180-220g), were randomly divided into normal control group (group A), epilepsy model group (group B), sodium valproate positive control group (group C), ginsenoside C-K Low, medium and high dose groups (groups D, E, F), 10 rats in each group. Sodium valproate was formulated with normal saline to the corresponding concentration according to the dose before the daily experiment, and ginsenosides C-K were for...

Embodiment 2

[0030] Example 2 Ginsenoside C-K intervenes in the acute epilepsy model induced by pentylenetetrazol

[0031] 1. Experimental method

[0032] 1.1 Dose Design and Grouping

[0033] The experiment was divided into normal control group, epilepsy model group, sodium valproate positive control group (400mg / kg), ginsenoside C-K low-dose group (80mg / kg), ginsenoside C-K medium-dose group (160mg / kg), ginsenoside C-K high dose group (320mg / kg). (See Table 3)

[0034] Table 3 Experimental grouping and dose design

[0035]

[0036] 1.2 Experimental steps

[0037] 60 SPF grade healthy male SD rats (body weight 180-220g), were randomly divided into normal control group (group A), epilepsy model group (group B), sodium valproate positive control group (group C), ginsenoside C-K Low, medium and high dose groups (groups D, E, F), 10 rats in each group. Sodium valproate was formulated with normal saline to the corresponding concentration according to the dose before the daily experime...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of ginsenoside C-K in preparation of an antiepileptic drug. it is verified through epileptic model animal experiments that ginsenoside C-K can remarkably prolong incubation period of epilepsy outbreak, reduce epilepsy outbreak intensity, shorten duration of epilepsy outbreak and lower body weight loss after outbreak. Through the above results, it shows that ginsenoside C-K can resist epilepsy outbreak and inhibit breakout and development of epilepsy disease.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to the new application of ginsenoside C-K in the preparation of antiepileptic drugs. Background technique [0002] Epilepsy is a brain disorder characterized by the persistence of permanent changes in the brain that produce seizures, with corresponding neurobiological, cognitive, psychological, and sociological consequences. There are about 70 million epilepsy patients in the world, more than 90% of them are located in low- and middle-income countries, and most of them are children and the elderly. According to statistics from the Chinese Anti-Epileptic Association, there are about 6 million active epilepsy patients in my country, and there are about 400,000 new epilepsy patients each year, which has become the second most common neurological disease. There are more than 30 kinds of antiepileptic drugs clinically, and the mechanism of their antiepileptic effect mainly includes regula...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7032A61P25/08
CPCA61K31/7032
Inventor 曾祥昌欧阳冬生胡凯陈露露周露萍王亚芹李超鹏李晓辉周宏灏
Owner 欧阳冬生
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com